The Lombardi Comprehensive Cancer Center (LCCC) supports high priority, innovative, pilot or phase I institutional trials focusing on initial early phase testing of a candidate agent or device for the diagnosis, prevention, detection or treatment of cancer. Potential institutional trials arise from LCCC's Research Programs and are developed within disease-focused groups. Letters-of-intent (LOIs) are submitted to LCCC's Protocol Review and Monitoring System (PRMS) Committee for scientific review and prioritization. If the proposed trial is requesting internal funding and is approved by PRMS, the LOI and PRMS reviews are forwarded to the Resource Allocation Subcommittee for Investigator Initiated Trials (RACIIT). RACIIT identifies those trials that are eligible for and merit Early Phase Clinical Research Support (EPCRS) or institutional funding. Once a PRMS-approved LOI is assured of funding, a full protocol can be written and submitted back to PRMS for final approval. If approved by the PRMS and the Institutional Review Board (IRB), previously committed funds are released to provide support for research nursing and/or data management through the Integrated Clinical Research Management Office (ICRMO), and, if designated, for correlative studies. The translation of basic science to the clinic has resulted in the testing of a series of agents that have been developed at LCCC. The strong emphasis on translational research and drug development is reflected in the development and clinical testing of agents targeting growth factors, oncogenic mutations, activated pathways and, more recently, immune checkpoints. These early phase clinical trials are developed on a background of bench-to-bedside-back to bench translational research. Thus, clinical trials can be born out of institutional basic science research (e.g., CDK4/6 inhibition in Gl cancers);out of a combination of clinical research interconnected with basic science research (e.g., PPARy + RXR agonist;Nilotinib + Cetuximab);or clinically driven research that requires strong basic scientific correlates (e.g., rational combination of temsirolimus plus capecitabine;a pilot study of stereotactic radiosurgery with concurrent gemcitabine, a pilot study of tremelimumab in patients with hepatocellular cancer, and studies testing the feasibility of using conditionally reprogrammed cells to predict treatment outcome).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-21
Application #
8698925
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2019-04-30
Budget Start
2014-09-09
Budget End
2015-04-30
Support Year
21
Fiscal Year
2014
Total Cost
$54,575
Indirect Cost
$19,478
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904
AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86
Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the ""Internet of Things"" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866
Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70
Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71
Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50
Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:
Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190

Showing the most recent 10 out of 883 publications